Kailera priced its initial public offering at $625 million, the largest capital raise for an obesity-focused biotech in market history. The company went public with institutional allocations oversubscribed before the roadshow concluded, according to filings reviewed Wednesday.

The IPO values Kailera at roughly $2.1 billion post-money, a multiple that places it above peer-stage companies in metabolic therapeutics despite limited clinical data. The offering sold 31.25 million shares at $20 per share, the high end of the $18-$20 range filed in early March. Lead underwriters included JPMorgan, Goldman Sachs, and Morgan Stanley. The company's pipeline centers on a dual-agonist obesity candidate currently in Phase 2 trials, with interim data expected in Q3 2025.

The raise reflects sustained institutional appetite for weight-loss drug exposure beyond Novo Nordisk and Eli Lilly, the two incumbents dominating the GLP-1 receptor agonist market. Kailera's lead asset targets GLP-1 and GIP receptors, a mechanism class now considered table stakes for competitive positioning. The company has not disclosed efficacy data, but CEO remarks during the roadshow emphasized differentiation through oral bioavailability and reduced gastrointestinal side effects. Those claims remain unvalidated.

For allocators, the IPO pricing signals two conditions: first, that growth managers are willing to pay forward multiples for optionality in a $100 billion+ addressable obesity market; second, that biotech IPO windows remain selective but open for categories with clear institutional sponsorship. Kailera's raise follows a 14-month drought in biotech offerings above $400 million, broken only by two oncology platforms in late 2024. The obesity thesis is now carrying sufficient conviction to reopen primary markets for pre-revenue names with credible science teams and venture backing from Arch Venture Partners, Foresite Capital, and a16z Bio.

Operators should track three follow-on events. Kailera's Phase 2 interim readout is scheduled for late Q3 2025, likely August or September, and will include weight-loss percentage data at 24 weeks versus placebo. A secondary offering is probable within 12-18 months if the data supports continued development, potentially raising another $300-$400 million to fund Phase 3 trials. Third, watch for M&A interest from Novo, Lilly, or Roche if Kailera demonstrates differentiated tolerability or convenience; those acquirers have paid $10-$15 billion for earlier-stage GLP-1 assets in the past 18 months.

The company now holds $625 million in cash against an estimated $180 million annual burn rate, providing runway through mid-2028 without additional capital. That margin matters in a market where biotech crossover funds remain underweight and public biotech indices have traded sideways since mid-2023.